Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.37 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | RHOA | P61586 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | SNCA | P37840 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL877587 | 0.86 | TSHR (0.41) | TSHRCYP3A4TDP1MAPTCACNA1B | |
| SCHEMBL7866089 | 0.84 | TSHR (0.42) | TSHRCYP3A4TDP1MAPTCACNA1B | |
| SCHEMBL194466 | 0.84 | TSHR (0.42) | TSHRCYP3A4TDP1MAPTCACNA1B | |
| SCHEMBL8165023 | 0.83 | TSHR (0.39) | TSHRCYP3A4TDP1MAPTCACNA1B | |
| SCHEMBL10454577 | 0.83 | MAPT (0.39) | TSHRCYP3A4TDP1MAPTCACNA1B | |
| SCHEMBL4675516 | 0.82 | TSHR (0.41) | TSHRCYP3A4TDP1MAPTCACNA1B | |
| SCHEMBL8517677 | 0.82 | TSHR (0.41) | TSHRCYP3A4TDP1MAPTCACNA1B | |
| SCHEMBL9778370 | 0.81 | TSHR (0.38) | TSHRCYP3A4TDP1MAPTCACNA1B | |
| SCHEMBL28947725 | 0.81 | TSHR (0.42) | TSHRCYP3A4TDP1MAPTCACNA1B | |
| SCHEMBL4673298 | 0.80 | TDP1 (0.41) | TSHRCYP3A4TDP1MAPTCACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1086093-B1 | TETRAHYDROQUINOLINE DERIVATIVES AS GLYCINE ANTAGONISTS | GLAXOSMITHKLINE SPA (IT) | 2005-08-10 | — | — | EP | disclosed |
| US-6495566-B2 | POTENT ANTAGONISTS AT THE STRYCHNINE INSENSITIVE GLYCINE BINDING SITE ASSOCIATED WITH THE N-METHYLASPARTIC ACID RECEPTOR COMPLEX | SMITHKLINE BEECHAM CORPORATION | 2002-12-17 | — | — | US | disclosed |
| US-20020169186-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS GLYCINE ANTAGONISTS | DI FABIO ROMANO (IT) | 2002-11-14 | — | — | US | disclosed |
| US-6413985-B1 | SELECTIVE ANTAGONISTS FOR THE STRYCHNINE INSENSITIVE GLYCINE BINDING SITE ASSOCIATED WITH THE NMDA RECEPTOR COMPLEX. | SMITHKLINE BEECHAM CORPORATION | 2002-07-02 | — | — | US | disclosed |
| US-20020052391-A1 | Tetrahydroquinoline derivatives as glycine antagonists | DI FABIO ROMANO (IT) | 2002-05-02 | — | — | US | disclosed |
| US-6362199-B1 | CENTRAL NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2002-03-26 | — | — | US | disclosed |
| EP-1086093-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS GLYCINE ANTAGONISTS | GLAXO WELLCOME S.p.A. (IT) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999064411-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS GLYCINE ANTAGONISTS | GLAXO WELLCOME SPA (IT) | 1999-12-16 | — | — | WO | disclosed |
| EP-0706543-B1 | MODULAR SYSTEM AND PROCESS FOR PRODUCING AQUEOUS COATING COMPOSITIONS | HERBERTS & CO GMBH (DE) | 1997-11-05 | — | — | EP | disclosed |
| EP-0706543-A1 | MODULAR SYSTEM AND PROCESS FOR PRODUCING AQUEOUS COATING COMPOSITIONS | Herberts Gesellschaft mit beschränkter Haftung (DE) | 1996-04-17 | — | — | EP | disclosed |
| WO-1995029960-A1 | MODULAR SYSTEM AND PROCESS FOR PRODUCING AQUEOUS COATING COMPOSITIONS | Herberts Gesellschaft mit beschränkter Haftung (DE) | 1995-11-09 | — | — | WO | disclosed |
| EP-0337422-A2 | Waterdilutable binders and their use as coatings especially in the car industry | Herberts Gesellschaft mit beschränkter Haftung (DE) | 1989-10-18 | — | — | EP | disclosed |
| EP-0260448-A2 | Externally cross-linkable binder combination, aqueous coating compositions containing it and its use | Herberts Gesellschaft mit beschränkter Haftung (DE) | 1988-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052391-A1 | Tetrahydroquinoline derivatives as glycine antagonists | GLRB, GLRA2, GLRA1 | TSHR 175/4885CYP3A4 984/4885TDP1 4518/4885 |
| US-20020169186-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS GLYCINE ANTAGONISTS | GLRA1, GRM1, GNMT | TSHR 1468/4885CYP3A4 240/4885TDP1 3915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.